Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patients with relapsed/refractory MCL, lenalidomide was approved by the US Food and Drug Administration for the treatment of relapsed/refractory MCL after failure of two prior therapies, one of which includes bortezomib, at a recommended starting dose of 25 mg on days 1-21 of each 28-day cycle. Lenalidomide enhanced the survival benefit in combination with rituximab in preclinical models, prompting clinical evaluation of the lenalidomiderituximab (R2) combination. In phase II trials, lenalidomide 20 mg on days 1-21 in combination with different standarddose rituximab schedules exhibited promising activity in both first-line and relapsed/refractory disease across multiple B-cell NHL subtypes. The feasibility of combining lenalidomide with immunochemotherapy, including R-CHOP and rituximab-bendamustine, has been demonstrated in phase I/II trials. These latter regimens are currently being evaluated in ongoing phase II and III trials. The role of lenalidomide monotherapy and R2 in maintenance therapy is also being examined. Based on available evidence, a comprehensive review of lenalidomide in all treatment phases of B-cell NHLrelapsed/refractory disease, first-line, and maintenance-is presented here.
introduction It is estimated that, in the USA, in 2015 there will be ∼70 800 new cases of non-Hodgkin lymphoma (NHL) and 18 990 deaths, accounting for a predicted 4% of new cancer diagnoses and 3% of cancer deaths [1] . Approximately 85% of NHL are of B-cell origin; the most common subtypes are aggressive diffuse large B-cell lymphoma (DLBCL), indolent follicular lymphoma (FL), and mantle cell lymphoma (MCL) [2, 3] . First-line treatment is usually immunochemotherapy, typically rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or bendamustine/rituximab (BR) [2, [4] [5] [6] . In MCL patients, induction may be followed by autologous stem cell transplantation (ASCT) or rituximab maintenance [7, 8] . Treatment of relapsed/refractory disease has lacked a standard of care with a broad range of chemoimmunotherapy and radioimmunotherapy options [2, 4, 9] . Subsequent relapses are characterized by a progressively shorter duration of response (DOR), underscoring the need for new agents capable of offering longer DORs with improved toxicity profiles.
Lenalidomide is an oral immunomodulator with direct antineoplastic activity and immunologic effects, including blocking tumor cell proliferation and angiogenesis, and stimulating T-cell-and natural killer (NK) cell-mediated cytotoxicity in experimental models [10] [11] [12] [13] [14] [15] [16] [17] . Antineoplastic and antiproliferative effects as well as increased NK cell numbers and activity were observed in vitro and in vivo against malignant lymphoma B-cells in general [11, 15, [17] [18] [19] and specifically against DLBCL, FL, and MCL cells [14, 16, 17, 20, 21] . In activated B-cell (ABC)-subtype DLBCL preclinical models, lenalidomideinduced cytotoxicity required the presence of cereblon to downregulate interferon regulatory factor-4 and B-cell receptor-NF-κB and to increase interferon-β production [21, 22] ; low cereblon expression is a possible resistance mechanism to lenalidomide.
This study provides a comprehensive overview of the clinical efficacy and safety of lenalidomide as monotherapy or in combinations for B-cell NHL including recent FDA approval of lenalidomide for relapsed/refractory MCL [23] , the emergence of lenalidomide/rituximab-based combination regimens, and initiation of numerous clinical trials.
lenalidomide monotherapy for relapsed/refractory NHL Lenalidomide was initially evaluated in several single-arm, multicenter phase II trials in relapsed/refractory NHL including a pilot study in indolent NHL (NHL-001) [24] , and two subsequent studies in aggressive NHL (NHL-002 and NHL-003; Table 1 ) [25, 27] . Lenalidomide was administered orally (PO) at a dose of 25 mg on days 1-21 of 28-day cycles (d1-21/28) for each trial and continued for 52 weeks (NHL-001 and NHL-002) or until disease progression (PD; NHL-003). NHL-001 enrolled 43 patients (mainly FL), including 67% refractory to rituximab and 50% refractory to their last treatment [24] . Overall response rates (ORRs) of 23%, including 7% complete response (CR) or unconfirmed CR (CRu), encouraged further study. Median progression-free survival (PFS) overall was 4.4 months (95% CI 2.5-10.4), whereas the median DOR for responders was >16.5 months at the time of reporting. NHL-002 enrolled 49 patients with aggressive relapsed/refractory disease (53% DLBCL, 31% MCL, and 10% FL grade 3); 58% refractory to rituximab [25] . Lenalidomide produced a 35% ORR, a median PFS of 4 months, and a 6.2-month median DOR. The activity of lenalidomide was notable in a subset of 15 MCL patients (5 of whom had received prior bortezomib and 5 prior ASCT) [26] . MCL patients had an ORR of 53%, including 3 (33%) with CR (1 prior bortezomib and 1 prior ASCT); the median PFS was 5.6 months with a median DOR of 13.7 months with responses ongoing at 12.7-27.6 months in CR patients.
The international NHL-003 study conducted in North America and Western Europe enrolled 217 patients with aggressive relapsed/refractory disease (50% DLBCL, 26% MCL, and 9% FL grade 3) [27] . ORR and CR/CRu rate were 35 and 13%, respectively. The median PFS overall was 3.7 months; a median DOR was 10.6 months (not reached at 9.2 months for CR/CRu patients). Longer follow-up of 57 MCL patients showed an ORR of 35 and 12% CR/CRu by independent central review [28] . After a median 20-month follow-up, a median DOR was 16.3 months (notably not reached at 31.8 months for CR patients).
Responses for MCL patients were independent of baseline characteristics, number of prior treatments, and prior ASCT, and paved the way for subsequent clinical study designs in MCL [28] . Retrospective review from NHL-002 and NHL-003 in 87 patients who relapsed after ASCT and were subsequently treated with lenalidomide showed an ORR of 39%, an outcome similar to 179 patients with no prior ASCT (35% ORR) [34] .
The prospective, international, single-arm phase II MCL-001 (EMERGE) trial enrolled 134 patients with MCL who had relapsed or were refractory to prior bortezomib [29] . Standard dosing of lenalidomide 25 mg/day, d1-21/28 continued until PD or intolerability. Key patient characteristics included 63% aged ≥65 years, 93% stage III-IV, 57% high tumor burden, 33% bulky disease, and 60% bortezomib-refractory. ORR and CR/ CRu rate by independent central review were 28 and 7.5%, respectively, with a median time to response (TTR) of 2.2 months, a median PFS of 4.0 months, and a median DOR of 16.6 months. Lenalidomide treatment demonstrated consistent ORR and DOR across subgroups per demographics, baseline disease characteristics, number of prior therapies, and response to prior therapies [29, 35] . Only high baseline lactate dehydrogenase levels, a known adverse prognostic factor for MCL, were associated with a significantly weaker response to lenalidomide. Median PFS was 4.0 months, and overall survival (OS) was 19.0 months [29] . On the basis of this study, lenalidomide was approved by the FDA in June 2013 for the treatment of relapsed/refractory MCL after two prior therapies, one of which includes bortezomib [23] . Longer follow-up for MCL-001 [36] and a combined analysis for the NHL-002, NHL-003, and MCL-001 studies have confirmed durable efficacy outcomes and a consistent safety profile for lenalidomide in relapsed/refractory MCL patients (Table 1) [30, 31] . An exploratory analysis of Ki-67 in 81/134 assessable patients from MCL-001 indicated that lenalidomide showed activity in patients with both low and high baseline Ki-67, with the lower baseline Ki-67 (<30% or <50%) associated with better CR rates, DOR, and survival than in those with elevated Ki-67 [36] .
A multicenter phase II UK study examined standard-dose lenalidomide followed by a lower maintenance dose in relapsed/ refractory MCL [33] . Twenty-six patients received lenalidomide 25 mg/day, d1-21/28 for six cycles, after which responders received maintenance lenalidomide 15 mg, days 1-21 until PD. An ORR was 31% with a median PFS of 3.9 months and a median DOR of 22.2 months. In patients who responded and received maintenance, the median PFS was 14.6 months and median OS has not yet been reached. Correlative studies demonstrated that responders had 40%-60% increases in peripheral T-and NK-cells during the first 6 months of treatment, with an initial dip in NK cells, suggesting infiltration into tumor sites.
Efficacy of lenalidomide was also examined within the two major molecular subgroups of DLBCL: germinal center B-celllike (GCB) and ABC (or non-GCB). In a retrospective analysis of 40 DLBCL of patients treated with single-agent lenalidomide, patients with tumors classified as non-GCB (versus GCB) by the Hans algorithm using immunohistochemistry achieved significantly a higher ORR (53% versus 9%; P = 0.006) and CR (24% versus 4%), and also had significantly longer median PFS (6.2 versus 1.7 months; P = 0.004) [37] . Median OS was similar between subgroups (14.0 and 13.5 months, respectively).
In Italy, 157 heavily pretreated, advanced-stage NHL patients ineligible to receive more intensive regimens were allowed offlabel treatment with lenalidomide [38] . Patients comprised 44% DLBCL, 35% MCL, 9% FL, and 6% transformed lymphoma (TL), with a median age of 70 years and median number of 3 prior therapies. Lenalidomide was generally dosed at 25 mg (61%) and as part of combination therapy (58%; 35% with dexamethasone and 10% with rituximab). Overall, 42% of patients responded to lenalidomide-based therapy, including 18% with CR/CRu; a median DOR was 7.8 months overall and 14.2 months for CR/CRu patients. By lymphoma subtype, an ORR was 45% for DLBCL, 39% MCL, 54% FL, and 33% TL. Overall, median PFS and OS were 5.7 and 21.8 months, respectively.
lenalidomide combinations
In preclinical studies, lenalidomide enhanced the survival benefit in conjunction with rituximab in a disseminated lymphoma-bearing severe combined immunodeficiency mouse xenograft model [16, 39] , which was associated with expansion of circulating NK cells and increased recruitment to tumor sites [16, 39, 40] . NK cell expansion by lenalidomide was mediated by stimulation of dendritic cells and alteration of the cytokine microenvironment, contributing to the augmentation of rituximab-associated antibody-dependent cellular cytotoxicity [17, 40] , without affecting CD20 density on lymphoma cells [39] . In cultured and freshly prepared MCL cells, lenalidomide enhanced rituximab-induced apoptosis by upregulating phosphorylation of c-Jun N-terminal protein kinases, Fas ligand, and granzyme B, as well as a series of apoptotic proteins [16, 17] .
R2
Lenalidomide plus rituximab (R2) has been evaluated in multiple phase II trials with variable dosing schedules and in multiple NHL subtypes (Table 2 ). In a phase I/II trial of relapsed/ refractory MCL patients, the maximum tolerated dose (MTD) of oral lenalidomide was identified as 20 mg, d1-21/28 with standard-dose rituximab 375 mg/m patients had received rituximab previously, and 27% had received bortezomib. During the phase II part of the study, R2 was highly active, showing a 57% ORR and 36% CR. Median TTR was 2 months, and a median DOR was 18.9 months. Median PFS and OS were 11.1 and 24.3 months, respectively.
R2 was also evaluated in MCL as a first-line therapy in a multicenter phase II study [42] . Induction treatment included 12 cycles of lenalidomide 20 mg/day d1-21/28 plus rituximab 375 mg/m 2 weekly during cycle 1, and then on day 1 of every other cycle (nine cycles total). R2 maintenance started at cycle 13, with the lenalidomide dose lowered to 15 mg, d1-21/28 plus rituximab every other cycle until PD. After a median follow-up of 24 months, 30 of 38 patients remain on treatment without PD, including 24 who completed induction and entered maintenance. An ORR was 84% (53% CR/CRu rate), median TTR was 2.8 months, and median DOR and PFS had not been reached.
In relapsed/refractory DLBCL or grade 3 FL (n = 45), R2 showed a 33% ORR (22% CR), a median DOR of 10.2 months, median PFS of 3.7 months, and median OS of 10.7 months [43] . In an Italian single-center phase II trial, 23 older patients (≥65 [49] . In 103 assessable patients, 90% responded, including 63% with CR/CRu. The ORR was 98%, 89%, and 80% in FL, MZL, and SLL, respectively, with a corresponding CR/CRu rate of 87%, 67%, and 23%. In the FL subset, responses were independent of Follicular Lymphoma International Prognostic Index (FLIPI) score, tumor bulk, or GELF criteria. Of 18/44 patients with detectable Bcl-2 by PCR at baseline, 89% achieved molecular response after six cycles. Estimated 3-year PFS was 75% overall and 79% for FL.
In a single-center phase II study of relapsed/refractory indolent lymphoma, 27 assessable patients (22 with FL) with a median of 3 prior therapies responded to R2 (lenalidomide 20 mg/day d1-21/28 plus rituximab 375 mg/m 2 day 15 cycle 1 and weekly for 4-8 doses, with four additional rituximab doses allowed if <CR after cycle 2) [46] . All patients showed a 74% ORR and a 44% CR/CRu rate (77% ORR and 41% CR/CRu in 22 FL patients). At a 43-month median follow-up, median DOR and PFS were 15.4 and 12.4 months, respectively.
The CALGB 50401 phase II study randomized patients with recurrent FL to lenalidomide (15 mg, cycle 1 and 20 mg, cycles 2-12; d1-21/28) alone or with rituximab (375 mg/m 2 weekly four times in cycle 1) [47] . All 89 assessable patients received rituximab-based treatment ≥6 months prior. The R2 regimen was more active than single-agent lenalidomide (ORR 75% versus 49%; CR 32% versus 13%) and exhibited significantly longer event-free survival (EFS; 2.0 versus 1.2 years; P = 0.0063). Based on these results, the multicenter phase II CALGB 50803 trial with R2 was initiated in patients with previously untreated grade 1-3A FL [48] . R2 was administered for 12 cycles, with lenalidomide 20 mg/day, d1-21/28 (an optional dose increase to 25 mg/day in cycles 2-12) plus rituximab weekly in cycle 1, day 1 of cycles 4, 6, 8, and 10. Among 57 assessable patients, ORR was 93% and CR 72%, with CR independent of FLIPI risk, histologic grade, or bulky disease. Median time to CR was 10 weeks; 92% of positron emission tomography (PET)-negative CRs were identified by 24 weeks.
lenalidomide plus dexamethasone
Based on potential synergy between lenalidomide and dexamethasone in MCL cells [20] and established clinical studies in multiple myeloma [58, 59] , lenalidomide 25 mg, d1-21/28 plus dexamethasone 40 mg weekly for ≤12 cycles was evaluated in relapsed/refractory MCL (n = 33) [50] . Patients received a median of 3 prior treatments; 36% had undergone ASCT, and 24% had received bortezomib. At treatment end, lenalidomidedexamethasone produced a 52% ORR and a 24% CR rate. Median DOR, PFS, and OS were 18, 12, and 20 months, respectively. In another single-center study, 27 patients with relapsed/ refractory indolent lymphoma or MCL resistant to rituximab received continuous lenalidomide 10 mg daily ± dexamethasone 8 mg/week ( part I), with rituximab 375 mg/m 2 /week four times added during cycle 3 ( part II) [51] . An ORR improved from 29% ( part I) to 58% (with a 33% CR rate) after part II; estimated PFS and DOR were 23.7 and 26.6 months, respectively, at a 12.2-month median follow-up. This combination showed activity in rituximab-resistant patients, while also improving tolerability to lenalidomide (with the addition of dexamethasone) manifest by fewer episodes of mild tumor flare and rash than generally experienced with lenalidomide.
lenalidomide plus bortezomib ± rituximab
Lenalidomide synergistically enhances bortezomib-induced cytotoxicity and apoptosis in B-cell lymphoma and primary cells [60] . The CALGB 50501 phase II study evaluated lenalidomide 20 mg, days 1-14 with bortezomib 1.3 mg/m 2 IV, days 1, 4, 8, and 11 in eight 3-week cycles in relapsed/refractory MCL (n = 54) [52] . Responders received maintenance lenalidomide 15 mg, days 1-14 and bortezomib, days 1 and 8 per cycle until PD. Forty percent of patients received ≥2 previous therapies, 85% prior rituximab, and 40% prior ASCT. Lenalidomide/bortezomib produced a 40% ORR and a 15% CR rate, with 6/8 CRs remaining in remission at a 3.2-year follow-up. Overall, 1-year EFS, PFS, and OS were 25%, 40% and 68%, respectively. The activity of this combination was considered disappointing given the high single-agent activity of both agents, and future studies using this dosing regimen do not appear to be warranted.
In a phase I study, the MTD of lenalidomide was identified as 10 mg, days 1-14 of a 3-week cycle when combined with bortezomib 1. [53] . This combination was administered to 22 MCL patients (16 first-line and 6 second-line), a majority with stage IV disease at diagnosis (82%). In 18 assessable patients, the ORR and CR rate were 82% and 32%, respectively. Among previously untreated patients, the ORR and CR rate were 75% and 25%, respectively. Estimated 18-month PFS and OS were 61% and 79%, respectively. Although active, the incidence of neuropathy (18% grade 3/4) associated with twice-weekly bortezomib infusions necessitated further investigation with a modified dosing schedule for optimal efficacy and safety.
R2-CHOP
Several groups have evaluated lenalidomide with R-CHOP given every 3 weeks (R2-CHOP21; Table 2 ). A phase I Mayo Clinic trial demonstrated that lenalidomide 25 mg, days 1-10 can be combined with standard-dose R-CHOP21 without causing dose delays or increased toxicity in aggressive B-cell lymphomas [61] . A phase II trial of R2-CHOP21 in 60 assessable patients reported a 98% ORR and an 80% CR rate, with a 24-month PFS of 59% [54] . A contemporary cohort from the Mayo Clinic Lymphoma Database of 87 consecutive DLBCL patients with similar risk characteristics who received R-CHOP21 alone showed a 24-month PFS of 52%. The non-GCB DLBCL subtype ( per IHC) had an inferior 24-month PFS with R-CHOP compared with GCB DLBCL (28% versus 64%, respectively). With R2-CHOP, the negative prognostic impact of the non-GCB phenotype appeared to be overcome with the addition of lenalidomide: 24-month PFS with R2-CHOP21 was 60% non-GCB versus 59% GCB patients. A French multicenter phase Ib dose-escalation study examined first-line lenalidomide (5, 10, 15, 20, or 25 mg) with longer dosing on days 1-14 with standard R-CHOP21 in 27 patients with mainly indolent NHL (18 FL, 4 DLBCL, 3 MCL, and 2 indolent unclassified) [62] . An ORR was 96%, with a 74% CR/CRu rate. On the basis of this study, first-line R2-CHOP21 (with lenalidomide at 25 mg/day, days 1-14) was evaluated in a multicenter phase II study of 80 patients with FL grade 1-3A and high tumor burden per GELF criteria [55] . R2-CHOP21 produced an ORR of 94% and a 74% CR/CRu rate, with 11% of patients progressing or relapsing during a median follow-up of 13 months.
The Fondazione Italiana Linfomi conducted a phase I study (REAL07) of first-line R2-CHOP21 in elderly patients (median age, 68 years) with DLBCL (including 5% FL grade 3B), where lenalidomide 15 mg/day, days 1-14 was identified as the MTD [63] . Final results from the phase II part of REAL07 showed that first-line R-CHOP21 with lenalidomide 15 mg/day, days 1-14 for six 21-day cycles (R2-CHOP21) was active in 49 DLBCL patients (median age, 69 years) [56] . R2-CHOP21 produced a 92% ORR and an 86% CR rate (PET-negative) after six treatment cycles. At a median follow-up of 28 months, 2-year PFS and OS were 80% and 92%, respectively. Patients with lowintermediate and intermediate-high/high risk according to IPI had 2-year PFS of 89% and 74%, respectively. Sixteen patients each with GCB versus non-GCB DLBCL ( per IHC) demonstrated an 88% ORR in each group and 2-year PFS of 71% versus 81%, respectively. These studies provide support for the combination of lenalidomide with standard R-CHOP21 in previously untreated NHL, including older patients and those with unfavorable prognostic profiles, in whom lenalidomide was given at 25 mg/day for 10 or 14 days in two studies [55, 61, 62] and 15 mg/day for 14 days of each 21-day cycle [63] .
R2-bendamustine
Some lymphoma patients are ineligible for or unable to tolerate anthracycline-based or high-dose chemotherapy. Because the BR combination has shown promising antilymphoma activity, the feasibility of combining R2 with bendamustine is under investigation. In the phase I SAKK 38/08 study in aggressive relapsed/refractory B-cell lymphoma, the MTD for lenalidomide was 10 mg, days 1-21 when combined with rituximab 375 mg/ m 2 , day 1 and bendamustine 70 mg/m 2 , days 1 and 2 of every 4-week cycle [64] . The Nordic Lymphoma Group MCL4 (LENA-BERIT) phase I/II study evaluated first-line R2-bendamustine for MCL patients aged >65 years. A phase I dose-escalation study identified an MTD for lenalidomide of 10 mg/day, days 1-14 [65] . Unexpected grade 3/4 cutaneous and allergic reactions led to a modified initial dosing schema, so that lenalidomide was initiated in cycle 2. Phase II induction treatment consisted of lenalidomide 10 mg/day, days 1-14, cycles 2-6; prednisolone 20 mg/day, days 1-14, cycle 2; and bendamustine 90 mg/m 2 , days 1-2 and rituximab 375 mg/m 2 , day 1 of six 4-week cycles [57] . Following induction, lenalidomide maintenance was provided on days 1-21 at 10 mg in cycles 7-8 and 15 mg in cycles 9-13. Preliminary efficacy data for 29 assessable patients showed a 97% ORR and a 79% CR/CRu rate with 61% of patients were negative for minimal residual disease after six cycles [57] . Estimated 2-year PFS and OS were 74% and 87%, respectively.
clinical safety of lenalidomide in singleagent and combination therapy
The safety profile of single-agent lenalidomide is predictable and manageable with dose modifications or supportive therapy. Table 3 presents a broad overview of select clinical studies that have published detailed safety results; studies not presented in Table 3 have published limited toxicity data to date. Hematologic myelosuppression is the most common grade 3/4 adverse event (AE) encountered overall. Non-hematologic events are predominantly grade 1/2 in severity, with pneumonia and fatigue being the most common grade 3/4 AEs in <10% of patients [29] . Grade 1/2 rash has been effectively managed with antihistamines or lowdose steroids [29] . Prophylaxis for thrombotic events is determined based on individual patient needs. Based on studies in multiple myeloma patients, the incidence of second primary malignancies (SPMs) over long-term treatment is also closely monitored. The SPM incidence was reported from the MCL-001 study was 2.21/100 person-years, similar to the age-adjusted incidence rate of 2.1/100 person-years for newly diagnosed, invasive cancer in individuals ≥65 years from the US SEER program [29, 66] .
R2 was generally well tolerated, with hematologic AE rates consistent with those for single-agent therapy. The rates of grade 3/4 hematologic toxicity with R2 varied across phase II studies, likely reflecting the different patient populations, NHL subtypes, and lines of therapy: neutropenia ranged from 30% to 66% and thrombocytopenia from 6% to 23% [41, 42, 44, 49] . Non-hematologic toxicity, mainly grade 1/2, also varied across studies, mostly consisting of fatigue, myalgia, rash, and infusionrelated reactions. In the randomized CALGB 50401 trial in recurrent indolent lymphoma, R2 and single-agent lenalidomide exhibited similar toxicity (grade 3/4 events: 52% versus 49%; 9% grade 4 in each arm), with a trend toward lower thrombotic risk with R2 (4% R2 versus 16% lenalidomide) [47] .
The R2-CHOP safety profile was generally consistent with that expected for R-CHOP. In two phase II trials, grade 4 neutropenia and thrombocytopenia were the most common [54, 55] . Febrile neutropenia was reported in <10% of patients in both trials. Other lenalidomide-based combinations (e.g. R2-bendamustine) have only been evaluated in small patient cohorts and require continued evaluation to better characterize their safety profiles.
dosing recommendations
Lenalidomide is approved by the US FDA for relapsed/refractory MCL at a dose of 25 mg, days 1-21 of each 28-day cycle based on the pivotal MCL-001 study [23, 29] . This dose has been modified to 10 mg with the same schedule for patients 
Italic values in the n's row are to differentiate the number of patients (i.e., "n") from data results.
a Included AEs regardless of causality. b Reported as infections overall.
-, denotes AEs that were not reported; AEs, adverse events; BTZ, bortezomib; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; dex, dexamethasone; DLBCL, diffuse large B-cell lymphoma; iNHL, indolent NHL; len, lenalidomide; maint., maintenance; MCL, mantle cell lymphoma; R2, lenalidomide + rituximab. with renal insufficiency, in the event of significant treatmentrelated toxicity or when used in maintenance or combination therapy [23, 29] .
The use of lenalidomide in other NHL types remains investigational, but has been evaluated using the same dosing regimen. The optimal use of lenalidomide in maintenance therapy is under active investigation; activity was shown at 15 mg, days 1-21 of each 28-day cycle [33, 42] . In combination with rituximab, a phase I study demonstrated an MTD of 20 mg lenalidomide [41] . The most common schedule of lenalidomide has been 20 mg, days 1-21 every 4 weeks in relapsed/refractory NHL [41, 43, 45, 47] and frontline MCL [42] , and 25 mg on days 1-10 [61], 25 mg on days 1-14 [62] , or 15 mg on days 1-14 [63] with first-line R-CHOP21.
Numerous clinical studies are planned or ongoing to evaluate the activity of first-line R2 ± chemotherapy or R2 consolidation/ maintenance, as well as the feasibility of R2-bendamustine in elderly patients in first-line therapy and beyond (Table 4) . Additional studies not shown here are being conducted in T-cell NHL, with initial results demonstrating activity with a similar tolerability profile in relapsed/refractory peripheral T-cell lymphoma and classical Hodgkin lymphoma [67, 68] . Results of ongoing studies will help establish optimal dosing for lenalidomide alone, in combination, and by line of therapy, as well as assist with determining the potential role for molecular-based therapeutic options in indolent and aggressive NHL.
conclusions
The FDA approval of lenalidomide in MCL was first established based on single-agent activity in relapsed/refractory patients. As summarized in this review, it is now apparent that lenalidomide is also active across multiple subtypes of indolent and aggressive NHL other than MCL. Preclinical evidence provided the basis for combining lenalidomide with rituximab, and the clinical activity of R2 led to ongoing evaluations in combination with chemotherapy. Dosing modifications were made to administer lenalidomide safely in combination-lowering the dose to 20 mg in R2 and adjusting the dose and frequency to the first 10-14 days of 3-week R-CHOP cycles. These studies have now led to large ongoing randomized trials of lenalidomide in all phases of NHL treatment that will determine the optimal use of this novel class of immunomodulatory drugs.
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